JBIO

+ Watchlist + Portfolio

Jade Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $22.55
52-Week Range: $6.71 – $28.00
Market Cap: $1.35B
P/E (TTM): —
EPS (TTM): -1.07
Dividend Yield: —

Advanced Metrics

Price/Book: 3.07
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 14.93
Debt/Equity: 0.00
Total Debt: $1.39M
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $974.31M

JBIO Income statement, annual periods, in USD
USD	FY2025
Revenue	$0.00
Research & Development	$93.12M
Selling, General & Admin	$20.42M
Operating Expenses	$113.54M
Operating Income	-$113.54M
EBITDA	-$113.52M
Pretax Income	-$127.35M
Income Tax	$58.00K
Net Income	-$127.41M
Diluted EPS	-3.19
Diluted Shares	31.36M

JBIO Cash Flow statement, annual periods, in USD
USD	FY2025
Operating Cash Flow	-$94.69M
Capital Expenditure	-$196.00K
Free Cash Flow	-$94.89M
Depreciation & Amortisation	$26.00K
Stock-Based Compensation	$20.01M
Investing Cash Flow	-$247.01M
Financing Cash Flow	$360.77M
Net Change in Cash	$19.07M

JBIO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$20.02M	$22.55M	$22.01M	$28.54M	$36.05M
Selling, General & Admin	$3.36M	$5.23M	$5.39M	$6.44M	$7.39M
Operating Expenses	$23.38M	$27.78M	$27.40M	$34.98M	$43.45M
Operating Income	-$23.38M	-$27.78M	-$27.40M	-$34.98M	-$43.45M
EBITDA	-$23.38M	-$27.77M	-$27.39M	-$34.97M	-$43.44M
Pretax Income	-$38.17M	-$32.13M	-$25.18M	-$31.87M	-$40.35M
Income Tax	$0.00	—	—	—	$16.00K
Net Income	-$38.17M	-$32.13M	-$25.18M	-$31.93M	-$40.37M
Diluted EPS	-1.18	-0.86	-0.48	—	-0.57
Diluted Shares	32.24M	28.43M	39.58M	—	57.78M

JBIO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$18.76M	-$20.16M	-$22.12M	-$33.65M	-$24.08M
Capital Expenditure	—	—	-$57.00K	-$3.00K	—
Free Cash Flow	-$18.76M	-$20.30M	-$22.18M	-$33.65M	-$24.08M
Depreciation & Amortisation	$0.00	$5.00K	$12.00K	$9.00K	$9.00K
Stock-Based Compensation	$2.42M	$3.90M	$4.29M	$9.40M	$7.41M
Investing Cash Flow	$0.00	-$136.00K	-$148.71M	-$98.16M	-$8.47M
Financing Cash Flow	-$700.00K	$191.31M	$0.00	$170.16M	-$795.00K
Net Change in Cash	-$19.46M	$171.01M	-$170.83M	$38.35M	-$33.35M

Market Snapshot

About

Jade Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics for metabolic and liver diseases. The company utilizes its proprietary drug discovery platforms to identify novel targets and develop small molecule and biological therapies. Jade is advancing a pipeline of product candidates addressing conditions including non-alcoholic steatohepatitis (NASH), metabolic dysfunction-associated liver disease, and related metabolic disorders. The company employs advanced screening technologies and translational research to accelerate drug development.